This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/072,540		02/08/2002	James Arthur Hoffmann	X-11368A	4243
25885	7590	01/14/2004		EXAMINER	
ELI LILLY	Y AND C	OMPANY	DELACROIX MUIRHEI, CYBILLE		
PATENT D P.O. BOX 6				ART UNIT	PAPER NUMBER
INDIANAP	INDIANAPOLIS, IN 46206-6288			1614	
				DATE MAILED: 01/14/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>							
	Application No.	Applicant(s)					
	10/072,540	HOFFMANN, JAMES ARTHUR					
Office Action Summary	Examiner	Art Unit					
	Cybille Delacroix-Muirheid	1614					
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	correspondence address					
• •	VIO OET TO EVOIDE 4 MONTH	(0) 50014					
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl' - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b)	36(a). In no event, however, may a reply be tin y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status	obruom, 2002						
 1) Responsive to communication(s) filed on <u>08 Fe</u> 2a) This action is FINAL. 2b) This 	action is non-final.						
, -		popultion as to the marite is					
3) Since this application is in condition for alloware closed in accordance with the practice under E							
Disposition of Claims							
4) Claim(s) 1-23 and 35-53 is/are pending in the application.							
4a) Of the above claim(s) is/are withdraw	wn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to.		•					
8) Claim(s) <u>1-23 and 35-53</u> are subject to restrict	ion and/or election requirement.						
Application Papers							
9) The specification is objected to by the Examine	r.						
10) The drawing(s) filed on is/are: a) acc		Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. §§ 119 and 120							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document: 2. Certified copies of the priority document: 3. Copies of the certified copies of the priori	s have been received. s have been received in Applicati	on No					
application from the International Bureau * See the attached detailed Office action for a list	ı (PCT Rule 17.2(a)).	_					
13) Acknowledgment is made of a claim for domesti since a specific reference was included in the firs 37 CFR 1.78.	c priority under 35 U.S.C. § 119(e	e) (to a provisional application)					
a) The translation of the foreign language pro							
14) Acknowledgment is made of a claim for domesti- reference was included in the first sentence of th		· · · · · · · · · · · · · · · · · · ·					
Attachment(s)							
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal P	(PTO-413) Paper No(s) ratent Application (PTO-152)					
l) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	6) Other: .						

Application/Control Number: 10/072,540

Art Unit: 1614

Detailed Action

The following is responsive to the preliminary amendment received Feb. 8, 2002.

New claims 35-53 are added. Claims 1-23 and 35-53 are presented for prosecution on the merits. PLEASE NOTE: Applicant has requested the cancellation of claims 24-34; however, no such claims are present in this application. Further clarification is respectfully requested. Furthermore, Applicant has requested priority to AN 09/573,809 filed June 1, 2000. However, AN 09/573,809 was NOT filed June 1, 2000, but was filed on May 18, 2000. Perhaps applicant intended to rely upon parent AN 09/585,181 which WAS filed June 1, 2000. Further clarification is respectfully requested.

Due to the complex nature of the claims no request for an oral election is being made. Please see MPEP 812.01.

Restriction/Election

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-10, drawn to a formulation, classified in class 514, subclass 12.
- II. Claims 11-23, 53 drawn to a method of treatment, classified in class 514, subclass 12.
- III. Claims 35-52, drawn to a stable pharmaceutical formulation, classified in class 514, subclass 12.

The inventions are distinct, each from the other because of the following reasons:

Inventions I or III and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1)

Application/Control Number: 10/072,540

Art Unit: 1614

the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the method can be practiced with a materially different product such as sulfonylurea compounds or insulin therapy. Additionally, the compositions in Groups I and III are independent and distinct because the composition of Group III requires the combination of a GLP-1 peptide or derivatives thereof, a tween surfactant, a preservative and a buffer, wherein the composition is to have a pH between 6.5-9.0. The GLP-1 composition of Group I does not require such a specific combination nor does the composition of Group I require the pH range of Group III.

Because these inventions are distinct for the reasons given above and the search required for one Group is not required for another, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is 703-306-3227. The examiner can normally be reached on Mon-Fri 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on 703-308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

CDM

Jan. 12, 2004

Cybille Delacroix-Muirheid Patent Examiner Group 1600